Supernus Pharmaceuticals (SUPN) Competitors $33.97 -0.10 (-0.29%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SUPN vs. OCUL, KNSA, INVA, PHAT, ARQT, JAZZ, CORT, PRGO, PCRX, and OMERShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Innoviva (INVA), Phathom Pharmaceuticals (PHAT), Arcutis Biotherapeutics (ARQT), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry. Supernus Pharmaceuticals vs. Ocular Therapeutix Kiniksa Pharmaceuticals Innoviva Phathom Pharmaceuticals Arcutis Biotherapeutics Jazz Pharmaceuticals Corcept Therapeutics Perrigo Pacira BioSciences Omeros Supernus Pharmaceuticals (NASDAQ:SUPN) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation. Does the media refer more to SUPN or OCUL? In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 3 articles in the media. Ocular Therapeutix's average media sentiment score of 0.78 beat Supernus Pharmaceuticals' score of 0.63 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of SUPN or OCUL? 59.2% of Ocular Therapeutix shares are owned by institutional investors. 9.3% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend SUPN or OCUL? Supernus Pharmaceuticals currently has a consensus price target of $36.00, indicating a potential upside of 5.98%. Ocular Therapeutix has a consensus price target of $16.57, indicating a potential upside of 59.49%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is SUPN or OCUL more profitable? Supernus Pharmaceuticals has a net margin of 0.83% compared to Ocular Therapeutix's net margin of -226.46%. Supernus Pharmaceuticals' return on equity of 0.56% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals0.83% 0.56% 0.40% Ocular Therapeutix -226.46%-52.75%-31.74% Does the MarketBeat Community prefer SUPN or OCUL? Supernus Pharmaceuticals received 38 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 72.99% of users gave Supernus Pharmaceuticals an outperform vote while only 70.05% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformSupernus PharmaceuticalsOutperform Votes47372.99% Underperform Votes17527.01% Ocular TherapeutixOutperform Votes43570.05% Underperform Votes18629.95% Which has more risk & volatility, SUPN or OCUL? Supernus Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Which has stronger valuation & earnings, SUPN or OCUL? Supernus Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$607.52M3.08$1.32M$0.09377.44Ocular Therapeutix$61.10M26.52-$80.74M-$1.35-7.70 SummarySupernus Pharmaceuticals beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.87B$7.02B$5.32B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio377.4412.25127.5316.08Price / Sales3.08396.061,490.6892.20Price / Cash22.0047.4339.5134.18Price / Book2.015.604.765.07Net Income$1.32M$153.56M$118.77M$225.46M7 Day Performance0.12%-1.46%-0.38%0.06%1 Month Performance6.16%15.32%6.06%3.93%1 Year Performance42.07%43.07%38.14%32.50% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals1.7903 of 5 stars$33.97-0.3%$36.00+6.0%+42.1%$1.87B$607.52M377.44580Upcoming EarningsHigh Trading VolumeOCULOcular Therapeutix4.1857 of 5 stars$10.53-5.0%$16.57+57.4%+225.7%$1.73B$58.44M-7.80267Upcoming EarningsKNSAKiniksa Pharmaceuticals2.6664 of 5 stars$22.59-1.8%$34.60+53.2%+48.4%$1.64B$270.26M-161.35220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageINVAInnoviva1.7061 of 5 stars$19.56-0.8%N/A+55.1%$1.23B$310.46M11.85112Upcoming EarningsPHATPhathom Pharmaceuticals1.154 of 5 stars$17.15-1.5%$22.50+31.2%+90.1%$1.04B$680,000.00-3.34110News CoverageARQTArcutis Biotherapeutics1.2913 of 5 stars$8.31-2.5%$13.33+60.4%+283.6%$971.36M$132.06M-3.79150JAZZJazz Pharmaceuticals4.7869 of 5 stars$110.03-2.8%$173.43+57.6%-13.3%$6.99B$3.83B18.912,800Upcoming EarningsCORTCorcept Therapeutics4.9234 of 5 stars$48.97+4.4%$65.25+33.2%+69.5%$4.90B$482.38M38.87300Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumePRGOPerrigo4.9081 of 5 stars$25.63+0.8%$37.00+44.4%-6.9%$3.47B$4.66B-27.869,140Upcoming EarningsDividend AnnouncementPCRXPacira BioSciences4.8181 of 5 stars$16.60-1.6%$24.20+45.8%-41.5%$778.16M$674.98M12.67720Upcoming EarningsNews CoveragePositive NewsOMEROmeros0.6943 of 5 stars$4.04-4.3%N/A+261.1%$244.54MN/A-1.72198 Related Companies and Tools Related Companies OCUL Alternatives KNSA Alternatives INVA Alternatives PHAT Alternatives ARQT Alternatives JAZZ Alternatives CORT Alternatives PRGO Alternatives PCRX Alternatives OMER Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SUPN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
